The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

An announcement from Innovent Biologics ( ($HK:1801) ) is now available. Innovent Biologics has announced the approval of SYCUME®, China’s first ...

Now, Japanese researchers are moving a promising, tooth-regrowing medicine into human trials. If the trial is successful, the ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of proteins, cytokines, and other biomarkers. These kits are widely used in drug ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Patients with irritable bowel syndrome are more likely to benefit from a diet that eliminates any food triggering an IgG ...